• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Another Ranbaxy facility stopped from making APIs for United States

News
Article

Ranbaxy Laboratories is being prohibited by FDA from manufacturing and distributing active pharmaceutical ingredients (APIs) from its Toansa, India, facility in order “to prevent substandard quality products from reaching U.S. consumers,” according to a news release.

Ranbaxy Laboratories is being prohibited by FDA from manufacturing and distributing active pharmaceutical ingredients (APIs) from its Toansa, India, facility in order “to prevent substandard quality products from reaching U.S. consumers,” according to a news release.

The agency inspected the Toansa facility in mid-January and found significant violations of current good manufacturing practice (CGMP) requirements. Staff of the facility had retested raw materials, intermediate drug products, and finished API after they had already failed analytical testing and specifications. The staff members wanted to produce acceptable findings and did not report or investigate the failures, according to FDA.

“Ranbaxy will not be permitted to resume manufacturing and distributing API for FDA-regulated drugs from the Toansa facility until the agency is satisfied that Ranbaxy has addressed its manufacturing quality issues at that facility,” FDA noted.

A third-party expert must be used to inspect the Toansa facility at Ranbaxy’s expense in order to certify that the facility is in compliance with CGMP.

For additional information on FDA’s regulatory activities for Ranbaxy, go to FDA’s website.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.